Cybrexa Therapeutics

company

About

Cybrexa Therapeutics is a cancer therapeutics company developing a new class of small molecule DNA repair.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$25M
Industries
Biotechnology,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active

Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and it will greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$25M
Cybrexa Therapeutics has raised a total of $25M in funding over 2 rounds. Their latest funding was raised on Mar 10, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 10, 2021 Series B $25M 1 Detail
Mar 2, 2018 Series B 1 Detail
Mar 2, 2018 Debt Financing 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Cybrexa Therapeutics is funded by 1 investors. Advantage Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Advantage Capital Series B